ContraVir Pharmaceuticals to Present at The MicroCap Conference 2017

EDISON, N.J., Oct. 03, 2017 -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today it will be featured as a presenting company at The MicroCap Conference, held in New York City on October  5, 2017.

James Sapirstein, Chief Executive Officer, of ContraVir will provide an overview of the Company's business and will be available to participate in one-on-one meetings with investors who are registered to attend the conference. 

Event:  The MicroCap Conference

Date:  October 5, 2017

Time:  11:00 – 11:30AM (Eastern Time)

Location:  The Essex House

About ContraVir Pharmaceuticals

ContraVir is a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies with a specific focus on developing a potentially curative therapy for hepatitis B virus (HBV). The Company is developing two novel anti-HBV compounds with complementary mechanisms of action. TXL™ currently in Phase 2, is designed to deliver high intrahepatic concentrations of TFV, while minimizing off-target side-effects caused by high levels of circulating TFV. CRV431, the other anti-HBV compound, is a next-generation cyclophilin inhibitor with a unique structure that increases its potency and selective index against HBV. ContraVir is also developing Valnivudine™, an orally available nucleoside analogue prodrug; Valnivudine™ is currently in Phase 3 for the treatment of herpes zoster. In addition to direct antiviral activity, Phase 2 data suggest that Valnivudine™ has the potential to reduce the incidence of debilitating shingles-associated pain known as post-herpetic neuralgia (PHN). For more information visit www.contravir.com.

For further information, please contact:

Sharen Pyatetskaya
Director of Investor Relations
[email protected]; (732) 902-4028